FindTrial
Sign In

Sambhav Program- an initiative to educate patients about Hepatitis C and help them manage the cost of treatment.

An Open-label, comparative, observational, multi-centric retrospective study to evaluate impact of financial support and counselor support on treatment access and compliance in chronic hepatitis C (HCV) patients; treated with peginterferon alfa/interferon in combination with ribavirin for HCV infection in a real-world clinical practice conditions.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2015/09/006206
Enrollment
600
Registered
2015-09-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic HCV infection

Interventions

None listed

Sponsors

MSD Pharmaceuticals Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Chronic HCV infection

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Impact of Sambhav on treatment access and complianceTimepoint: 6 months duration for collection of data retrospectively—

Secondary

MeasureTime frame
NoneTimepoint: None—

Countries

India

Contacts

Public ContactDr Ajit Sood

Dayanand Medical College and Hospital

ajitsood10@gmail.com09803028289

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026